Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Assets Average (2020 - 2026)

InMed Pharmaceuticals has reported Assets Average over the past 5 years, most recently at $12.3 million for Q4 2025.

  • For Q4 2025, Assets Average rose 29.45% year-over-year to $12.3 million; the TTM value through Dec 2025 reached $12.3 million, up 29.45%, while the annual FY2025 figure was $13.7 million, 5.68% up from the prior year.
  • Assets Average for Q4 2025 was $12.3 million at InMed Pharmaceuticals, down from $14.5 million in the prior quarter.
  • Over five years, Assets Average peaked at $18.4 million in Q4 2021 and troughed at $8.9 million in Q1 2025.
  • A 5-year average of $13.6 million and a median of $13.6 million in 2021 define the central range for Assets Average.
  • On a YoY basis, Assets Average climbed as much as 29.85% in 2025 and fell as far as 37.86% in 2025.
  • Year by year, Assets Average stood at $18.4 million in 2021, then dropped by 14.18% to $15.8 million in 2022, then decreased by 16.92% to $13.1 million in 2023, then fell by 27.53% to $9.5 million in 2024, then rose by 29.45% to $12.3 million in 2025.
  • Business Quant data shows Assets Average for INM at $12.3 million in Q4 2025, $14.5 million in Q3 2025, and $12.4 million in Q2 2025.